Form 4: Lilly Endowment Sells LLY Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 1,390 shares of common stock for approximately $1,085.01 per share.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the sale of 1,390 shares of common stock.
• The transaction occurred on January 5, 2026.
• Shares were sold at a weighted average price of $1,085.011, with prices ranging from $1,085.00 to $1,085.10.
• Following the transaction, Lilly Endowment Inc. beneficially owns 92,189,126 shares of Eli Lilly & Co. common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: Neutral. The sale by a 10% owner could be seen as slightly negative, but the small quantity relative to total holdings and the execution under a 10b5-1 plan mitigate any strong negative sentiment, suggesting a routine portfolio adjustment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to new, negative information.

Negatives

• A 10% owner sold 1,390 shares of common stock.

Management Comments

• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.00 to $1,085.10, inclusive.
• The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

Industry Context

This Form 4 filing reports an insider transaction by a significant shareholder of Eli Lilly & Co., a major pharmaceutical company. Such routine sales by large institutional holders, especially when pre-planned under a 10b5-1 plan, are generally not indicative of broader industry trends but rather portfolio management decisions.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a significant institutional investor under a pre-planned arrangement is unlikely to have a material impact on other shareholders or the company's stock price.

Key Dates

Recommendation

The Form 4 reports a routine, pre-planned sale of a very small percentage of shares by a 10% owner. This transaction does not provide new information that would warrant a change in investment thesis for Eli Lilly & Co. and is unlikely to impact the stock price significantly. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Eli Lilly, LLY, Lilly Endowment, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Pharmaceuticals